DeCure for Brain small vessel disease 1 with or without ocular anomalies
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for brain small vessel disease 1 with or without ocular anomalies — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrain small vessel disease 1 with or without ocular anomalies maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brain small vessel disease 1 with or without ocular anomalies is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type IV alpha 1 chain (COL4A1) — COL4A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NAY · 1.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Cerebral small vessel disease (CSVD) is the most common chronic vascular disease involving the whole brain, but its exact pathogenesis remains unclear. Sporadic forms are very common, with risk factors including increasing age, hypertension, smoking, and diabetes; the cause of the vessel abnormalities in sporadic disease is not well understood, and brain damage is generally attributed to ischaemia secondary to the vessel abnormality, though evidence for altered microvessel function and blood-brain barrier failure is accumulating. A 2005 review noted that clinical trials suggested a therapeutic benefit of acetylcholinesterase inhibitors for acquired small vessel disease, but no specific drug is named in the abstracts as having proven efficacy in CSVD, and the 2022 review states that many problems remain in treatment.
Rare monogenic forms are well described. Cerebral autosomal-dominant arteriopathy with stroke and ischaemic leukoencephalopathy (CADASIL) is caused by mutations in the Notch3 gene. A 2020 case study of two adolescent patients with Axenfeld-Rieger anomaly and neuropsychiatric symptoms found that cerebral magnetic resonance imaging showed white matter T2-hyperintensities suspective of CSVD; genetic analysis revealed pathogenic mutations in the FOXC1 gene in one patient and the COL4A1 gene in the other. The cerebral lesions involved frontotemporal regions that control social behaviour, executive and cognitive function, suggesting neuropsychiatric symptoms may be early clinical presentations of genetically determined CSVD.
Other rare cerebral microangiopathies include cerebral amyloid angiopathy, which predisposes to lobar haemorrhages, and conditions such as mitochondrial cytopathies, Fabry's disease, and toxemic vasculopathy, which the 2005 review states offer established or new therapeutic options, though no specific drugs or outcomes are given. The 2018 review lists oxidative stress, inflammatory reaction, amyloid beta deposition, vascular endothelial dysfunction, and blood-brain barrier damage as implicated in pathogenesis, but the exact mechanisms remain unclear.
What is still missing is a clear understanding of the pathogenesis of sporadic CSVD, validated biomarkers for diagnosis and monitoring, and definitive clinical trial data for any drug treatment. Patient stratification by monogenic cause versus sporadic disease, and by imaging or biochemical markers, is not yet established. Funding for large, well-designed trials that can test specific interventions against hard endpoints like stroke or dementia is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 2005 · 69 citations
Cerebral small vessel diseases: cerebral microangiopathies
AbstractPURPOSE OF REVIEW: Small vessel diseases of the brain are still clinically underrecognized whereas their burden is increasing steeply. The most frequent is acquired degenerative small vessel disease. Many hereditary or idiopathic small vessel diseases have also been identified, of which cerebral autosomal-dominant arteriopathy with stroke and ischaemic leukoencephalopathy (CADASIL) is the most prominent. In this review, we will highlight current evidence on pathophysiology and genetics, new imaging tools, and treatment options. RECENT FINDINGS: Recent imaging studies have stressed the disruption of white matter connections in the pathogenesis of cognitive impairment in acquired small vessel disease. Clinical trials suggest a therapeutic benefit of acetylcholinesterase inhibitors. CADASIL is caused by mutations in the Notch3 gene. Current basic research has identified Notch genes to be important for endothelial and smooth muscle cells to form arteries and veins. Diagnosis can now be made reliably by magnetic resonance brain imaging, skin biopsy, or genetic testing. The so-called retinocerebral vasculopathies share the involvement of both retinal, cerebral and cochlear arterioles (e.g. Susac's syndrome). Cerebral amyloid angiopathy, occurring either sporadically or as a cause of various gene mutations, predisposes to lobar haemorrhages caused by rupture of affected small cortical vessels. Other rare cerebral microangiopathies, such as mitochondrial cytopathies, Fabry's disease and toxemic vasculopathy, offer established or new therapeutic options. SUMMARY: Cerebral small vessel diseases are highly variable in their aetiopathogenesis and clinical course. Current pathophysiological insights will help develop better treatment modalities; new imaging tools will provide surrogate markers for monitoring disease progression and treatment effects.
Frontiers in Neurology · 2022 · 45 citations · open access
Cerebral Small Vessel Disease: Neuroimaging Features, Biochemical Markers, Influencing Factors, Pathological Mechanism and Treatment
AbstractCerebral small vessel disease (CSVD) is the most common chronic vascular disease involving the whole brain. Great progress has been made in clinical imaging, pathological mechanism, and treatment of CSVD, but many problems remain. Clarifying the current research dilemmas and future development direction of CSVD can provide new ideas for both basic and clinical research. In this review, the risk factors, biological markers, pathological mechanisms, and the treatment of CSVD will be systematically illustrated to provide the current research status of CSVD. The future development direction of CSVD will be elucidated by summarizing the research difficulties.
Axenfeld-Rieger Anomaly and Neuropsychiatric Problems—More than Meets the Eye
AbstractAbstract Objective The main purpose of this article is to demonstrate the co-occurrence of Axenfeld-Rieger anomaly and neuropsychiatric problems as clinical signs of genetically determined cerebral small vessel disease in two patients. Case Study We report on two adolescent individuals with ocular anterior segment dysgenesis (Axenfeld-Rieger anomaly) presenting with neuropsychiatric symptoms. Both patients underwent cerebral magnetic resonance imaging showing white matter T2-hyperintensities involving different brain regions, suspective of cerebral small vessel disease. Genetic analysis revealed pathogenic mutations in the FOXC1 gene (patient 1) and the COL4A1 gene (patient 2), respectively. Conclusion We report on the co-occurrence of ocular anterior segment dysgenesis (Axenfeld-Rieger anomaly) and neuropsychiatric symptoms as clinical signs of genetically determined cerebral small vessel disease in two patients. In both patients, the cerebral lesions involved the frontotemporal regions, brain regions that control social behavior as well as executive and cognitive function, highlighting the fact that neuropsychiatric symptoms may be early clinical presentations of cerebral small vessel disease. We further provide a review of monogenic causes of pediatric cerebral small vessel disease, emphasizing the links to childhood-onset neuropsychiatric disease.
Oxford University Press eBooks · 2020 · 0 citations
Small vessel disease
Abstract‘Small vessel disease’ describes a combination of neuroradiological and clinical features that are due to an intrinsic disorder of the small cerebral arterioles, capillaries, and venules in varying proportions. It is very common, usually sporadic, although rare monogenic forms are well described. The commonest presentations are with stroke or cognitive impairment. The cause of the small vessel abnormalities in the sporadic form is not well understood and the brain damage is generally attributed to ischaemia secondary to the vessel abnormality. However, evidence for altered microvessel function and blood brain barrier failure is accumulating. The commonest risk factors are increasing age, hypertension, smoking, and diabetes, but environmental and lifestyle factors are also important although poorly understood. Whether the imaging features or incidence of small vessel-related stroke or dementia vary by world region is unknown. We review current knowledge on presentation, aetiology, incidence, and prevalence of sporadic small vessel disease.
AbstractWith some success the contributors to this book have tried to summarize what is known of the pathogenesis, clinical features, imaging characteristics and pathology of small vessel arterial disease in the brain. They have highlighted the historical background to this and have gone on to discuss the extent to which there is an overlap between the classification and description of small vessel arterial disease. The concepts and terminology have changed since the initial descriptions of arterial disease due to the advent of scanners to image the brain in life.
Advances in pathogenesis of cerebral small vessel disease
AbstractWith the development of imaging, molecular biology, and pathology, the pathogenesis of cerebral small vessel disease (CSVD) has been deeply understood, but the exact pathogenesis is still unclear. This article reviews the pathogenesis of CSVD, including oxidative stress, inflammatory reaction, amyloid beta amyloid deposition, vascular endothelial dysfunction, and blood-brain barrier damage.
Key words:
Cerebral Small Vessel Diseases; Endothelium, Vascular; Oxidative Stress; Inflammation; Amyloid β-Peptides; Blood-Brain Barrier; Genetic Predisposition to Disease
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
